Moreover, as TGF‐β members such as activin A, activin B, growth differentiation factor‐11, and myostatin have been associated with or shown to induce skeletal muscle wasting in cancer and non‐cancer settings, targeting of the ACVR2B receptor has become a promising therapeutic approach in combating cachexia.14, 15, 16, 17, 18, 19, 20, 21. Here, MSTN is linked to cancer.